{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:40:05Z","timestamp":1783662005782,"version":"3.55.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In May 2019, the US Food and Drug Administration (FDA) released the Framework for FDA\u2019s Real-World Evidence (RWE) Program, a draft guidance to evaluate the potential use of real-world data in facilitating regulatory decisions. As a result, pharmaceutical companies and medical communities see patient registries, which are large, prospective, noninterventional cohort studies, as becoming increasingly important in providing evidence of treatment effectiveness and safety in clinical practice. Patient registries are designed to collect longitudinal clinical data on a broad population to address critical medical questions over time. With their large sample sizes and broad inclusion criteria, patient registries are often used to generate RWE in the general and underrepresented patient populations that are less likely to be studied in controlled clinical trials. Here, we describe the value of industry-sponsored patient registries in oncology\/hematology settings to healthcare stakeholders, in drug development, and in fostering scientific collaboration.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad110","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:34:37Z","timestamp":1686184477000},"page":"657-663","source":"Crossref","is-referenced-by-count":2,"title":["The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research"],"prefix":"10.1093","volume":"28","author":[{"given":"E Dawn","family":"Flick","sequence":"first","affiliation":[{"name":"Worldwide Health Economics and Outcomes Research (HEOR), Bristol Myers Squibb , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R","family":"Terebelo","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute , Southfield, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fish","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics and Outcomes Research (HEOR), Bristol Myers Squibb , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Bristol Myers Squibb , Summit, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Corporate Medical Affairs, Global Scientific Communications, Bristol Myers Squibb , Summit, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Nifenecker","sequence":"additional","affiliation":[{"name":"Research and Early Development Alliances, Bristol Myers Squibb , Summit, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics and Outcomes Research (HEOR), Bristol Myers Squibb , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thaler","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Bristol Myers Squibb , Summit, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ussery","sequence":"additional","affiliation":[{"name":"US Medical Affairs, Bristol Myers Squibb , Summit, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Grinblatt","sequence":"additional","affiliation":[{"name":"NorthShore University HealthSystem , Evanston, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2023080322081142900_CIT0001","author":"U.S. Food and Drug Administration","year":"2018"},{"issue":"2","key":"2023080322081142900_CIT0002","first-page":"18","article-title":"The value of observational cohort studies for cancer drugs","volume":"7","author":"Spigel","year":"2010","journal-title":"Biotechnol Healthc"},{"issue":"4","key":"2023080322081142900_CIT0003","first-page":"211","article-title":"Patient registries: a new gold standard for \u201creal world\u201d research","volume":"4","author":"Trotter","year":"2002","journal-title":"Ochsner J"},{"key":"2023080322081142900_CIT0004","author":"Agency for Healthcare Research and Quality"},{"issue":"2","key":"2023080322081142900_CIT0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10147-009-0879-2","article-title":"Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer","volume":"14","author":"Buyse","year":"2009","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"2023080322081142900_CIT0006","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.annemergmed.2011.05.024","article-title":"Understanding commonly encountered limitations in clinical research: an emergency medicine resident\u2019s perspective","volume":"59","author":"Jones","year":"2012","journal-title":"Ann Emerg Med"},{"issue":"9","key":"2023080322081142900_CIT0007","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"2023080322081142900_CIT0008","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2217\/fon-2019-0013","article-title":"INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma","volume":"15","author":"Costello","year":"2019","journal-title":"Future Oncol"},{"issue":"19","key":"2023080322081142900_CIT0009","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1002\/cncr.27513","article-title":"Racial differences in presentation and management of follicular non-hodgkin lymphoma in the United States: report from the National LymphoCare study","volume":"118","author":"Nabhan","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2023080322081142900_CIT0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clon.2014.12.002","article-title":"Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study","volume":"27","author":"Wozniak","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"19","key":"2023080322081142900_CIT0011","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cncr.33089","article-title":"Association between race and treatment patterns and survival outcomes in multiple myeloma: a Connect\u00ae MM registry analysis","volume":"126","author":"Ailawadhi","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"2023080322081142900_CIT0012","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjh.13895","article-title":"Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era","volume":"172","author":"Nastoupil","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2023080322081142900_CIT0013","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","article-title":"Connect\u00ae MM registry: the importance of establishing baseline disease characteristics","volume":"15","author":"Rifkin","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2023080322081142900_CIT0014","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clon.2014.03.001","article-title":"Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study","volume":"26","author":"Hurwitz","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"14","key":"2023080322081142900_CIT0015","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from RegistHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023080322081142900_CIT0016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrc1948","article-title":"The evolution of the population-based cancer registry","volume":"6","author":"Parkin","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2023080322081142900_CIT0017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sder.2010.01.001","article-title":"Assessing long-term drug safety: lessons (re) learned from Raptiva","volume":"29","author":"Seminara","year":"2010","journal-title":"Semin Cutan Med Surg"},{"issue":"12","key":"2023080322081142900_CIT0018","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"issue":"10","key":"2023080322081142900_CIT0019","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-014-2099-8","article-title":"Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2023080322081142900_CIT0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jha2.67","article-title":"Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: results from the Connect\u00ae CLL registry","volume":"1","author":"Sharman","year":"2020","journal-title":"eJHaem"},{"issue":"Suppl 1","key":"2023080322081142900_CIT0021","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jval.2018.04.022","article-title":"Health-related quality of life assessments predict relapse or death in patients with newly diagnosed multiple myeloma (MM): results from the Connect\u00ae MM registry","volume":"21","author":"Wagner","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"2023080322081142900_CIT0022","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-017-3176-x","article-title":"Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States","volume":"17","author":"Nabhan","year":"2017","journal-title":"BMC Cancer"},{"issue":"7","key":"2023080322081142900_CIT0023","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-021-00524-1","article-title":"Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect\u00ae MM registry","volume":"11","author":"Lee","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"2023080322081142900_CIT0024","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1080\/10428194.2018.1427860","article-title":"Reasons for initiation of treatment and predictors of response for patients with Rai stage 0\/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect\u00ae CLL cohort study","volume":"59","author":"Flowers","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023080322081142900_CIT0025","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"2023080322081142900_CIT0026","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the Connect\u00ae MM registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023080322081142900_CIT0027","author":"National Comprehensive Cancer Network"},{"issue":"11","key":"2023080322081142900_CIT0028","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/annonc\/mdv375","article-title":"Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National LymphoCare study","volume":"26","author":"Casulo","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"2023080322081142900_CIT0029","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"25","key":"2023080322081142900_CIT0030","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/bloodadvances.2017011262","article-title":"Early progression of disease as a predictor of survival in chronic lymphocytic leukemia","volume":"1","author":"Ahn","year":"2017","journal-title":"Blood Adv"},{"key":"2023080322081142900_CIT0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s12885-016-2710-6","article-title":"Connect\u00ae MDS\/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study","volume":"16","author":"Steensma","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"2023080322081142900_CIT0032","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clml.2017.11.010","article-title":"Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization\/cytogenetics: a real-world clinical experience in the Connect\u00ae CLL registry","volume":"18","author":"Mato","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2023080322081142900_CIT0033","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/ijlh.13400","article-title":"Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes","volume":"43","author":"Patel","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2023080322081142900_CIT0034","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jha2.16","article-title":"Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect\u00ae MDS\/AML disease registry","volume":"1","author":"Pollyea","year":"2020","journal-title":"eJHaem"},{"issue":"17","key":"2023080322081142900_CIT0035","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.28710","article-title":"Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer","volume":"120","author":"Kaufman","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"2023080322081142900_CIT0036","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2018.04.007","article-title":"Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect\u00ae MM registry (2010-2016)","volume":"18","author":"Jagannath","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023080322081142900_CIT0037","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1471-2407-14-307","article-title":"The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer","volume":"14","author":"Tripathy","year":"2014","journal-title":"BMC Cancer"},{"issue":"12","key":"2023080322081142900_CIT0038","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1634\/theoncologist.2012-0190","article-title":"Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study","volume":"17","author":"Bendell","year":"2012","journal-title":"Oncologist"},{"issue":"23","key":"2023080322081142900_CIT0039","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1002\/cncr.27609","article-title":"Head and neck carcinoma in the United States: first comprehensive report of the longitudinal oncology registry of head and neck carcinoma (LORHAN)","volume":"118","author":"Ang","year":"2012","journal-title":"Cancer"},{"issue":"Suppl","key":"2023080322081142900_CIT0040","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.HS9.0000846720.60768.ed","article-title":"P963: evolution of treatment patterns and overall survival in patients with relapsed\/refractory multiple myeloma receiving a second line of therapy between 2012 and 2020: analysis of the PREAMBLE cohort","volume":"6","author":"Kuter","year":"2022","journal-title":"HemaSphere"},{"issue":"23","key":"2023080322081142900_CIT0041","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a Prospective Registry of Men with Metastatic Castration-Resistant Prostate Cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"issue":"Suppl 3","key":"2023080322081142900_CIT0042","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/j.jval.2019.09.417","article-title":"S479. Healthcare resource utilization and costs associated with different treatment modalities in relapsed\/refractory multiple myeloma patients in four european countries: findings from PREAMBLE","volume":"22","author":"Goldschmidt","year":"2019","journal-title":"Value Health"},{"issue":"33","key":"2023080322081142900_CIT0043","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023080322081142900_CIT0044","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023080322081142900_CIT0045","author":"National Comprehensive Cancer Network"},{"issue":"7","key":"2023080322081142900_CIT0046","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.3633","article-title":"Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study","volume":"23","author":"Grothey","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2023080322081142900_CIT0047","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023080322081142900_CIT0048","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"2023080322081142900_CIT0049","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann Oncol"},{"key":"2023080322081142900_CIT0050","author":"National Comprehensive Cancer Network"},{"key":"2023080322081142900_CIT0051","author":"National Comprehensive Cancer Network"},{"key":"2023080322081142900_CIT0052","author":"National Comprehensive Cancer Network"},{"issue":"7","key":"2023080322081142900_CIT0053","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.clinthera.2018.05.017","article-title":"Treatment outcomes and health care resource utilization in patients with newly diagnosed multiple myeloma receiving lenalidomide-only maintenance, any maintenance, or no maintenance: results from the Connect\u00ae MM registry","volume":"40","author":"Rifkin","year":"2018","journal-title":"Clin Ther"},{"issue":"29","key":"2023080322081142900_CIT0054","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023080322081142900_CIT0055","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.28659","article-title":"The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States","volume":"120","author":"Nastoupil","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"2023080322081142900_CIT0056","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/10428194.2014.935366","article-title":"Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry","volume":"56","author":"Grinblatt","year":"2015","journal-title":"Leuk Lymphoma"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/657\/51034831\/oyad110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/657\/51034831\/oyad110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:09:27Z","timestamp":1691100567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/657\/7191660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad110","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,6,7]]}}}